COST
53
2
TDC
63
3
DRI
45
5
EOG
62
6
PG
20
-2
LNC
40
-2
PYPL
32
3
ED
50
-9
PNR
30
-2
HP
36
2
AMT
39
3
PM
41
2
FIS
48
2
MDLZ
34
4
PCAR
56
11
HOG
48
3
IBM
67
3
BMY
66
-3
MSI
47
3
SHW
43
-3
COST
53
2
TDC
63
3
DRI
45
5
EOG
62
6
PG
20
-2
LNC
40
-2
PYPL
32
3
ED
50
-9
PNR
30
-2
HP
36
2
AMT
39
3
PM
41
2
FIS
48
2
MDLZ
34
4
PCAR
56
11
HOG
48
3
IBM
67
3
BMY
66
-3
MSI
47
3
SHW
43
-3
Financhill
Back

Dianthus Therapeutics, Inc. 10K Form

Buy
63

DNTH
Dianthus Therapeutics, Inc.

Last Price:
$85.96
Seasonality Move:
-10.63%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive DNTH News And Ratings

See the #1 stock for the next 7 days that we like better than DNTH

DNTH Financial Statistics

Sales & Book Value

Annual Sales: $2M
Cash Flow: $-47.1M
Price / Cash Flow: 0
Annual Sales: $11.42
Price / Book: 9.38

Profitability

EPS (TTM): -4.11290
Net Income (TTM): $-162.3M
Gross Margin: $1.6M
Return on Equity: -40.1%
Return on Assets: -37.62%

Dianthus Therapeutics, Inc. Earnings Forecast

Key Dianthus Therapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 10 years for DNTH is 78.98%.
  • The Selling, General & Administrative Expenses for DNTH have been equal to 1,686.20% of Gross Profit Margin.
  • The Research & Development expenses have been 7,153.14% of Revenue.
  • The Net Earning history of DNTH is -7,973.33% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 5 years.

Dianthus Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: DNTH
Website: dianthustx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 13.32
Quick Ratio: 13.16

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

DNTH Technical Analysis vs Fundamental Analysis

Buy
63
Dianthus Therapeutics, Inc. (DNTH) is a Buy

Is Dianthus Therapeutics, Inc. a Buy or a Sell?